Nautilus Biotechnology develops a single-molecule proteome analysis platform for measuring proteins and proteoforms across the human proteome. Company news centers on the Voyager™ Platform, Iterative Mapping, the Tau Proteoforms assay, early access customer activity, and collaborations that apply isoform-resolved proteomics to cancer and neurodegenerative disease research.
Updates also cover quarterly financial results, operating outlook, commercial-readiness activity, senior sales leadership, scientific conference presentations, and investor-conference participation. The company's disclosures frame Nautilus as a development-stage life sciences tools business moving its proteomics platform from validation and field evaluation toward broader customer access.
Nautilus Biotechnology (NAUT) reported a third-quarter 2026 net loss of $15.636 million, wider than the corresponding prior-year period. Revenue was $234,000 versus none a year earlier, comprising grant and service revenue. Operating expenses rose to $16.947 million from $15.472 million, while net loss per share widened to $0.12 from $0.11.
For the nine months ended September 30, revenue reached $424,000 and net loss narrowed to $44.802 million from $45.220 million. Operating cash use increased to $40.107 million from $38.321 million. Cash, cash equivalents and investments totaled $114.3 million at September 30. Nautilus plans twenty assays through mid-2028 and instrument availability in mid-2027. After quarter-end, it announced participation in the four-year, ARPA-H-funded SEEDS research consortium, expecting up to $6 million to deploy Voyager to measure proteoforms, different forms of proteins, involved in Alzheimer’s disease and cancer.
Nautilus Biotechnology (NAUT) expects to receive up to $6 million through its participation in the four-year SEEDS protein research consortium. Co-led by the Buck Institute for Research on Aging and Georgetown University, SEEDS was awarded up to $51.7 million by the Advanced Research Projects Agency for Health.
Nautilus will deploy its Voyager Platform to measure proteoforms, distinct versions of proteins, initially studying Alzheimer’s disease and Ewing sarcoma. The consortium aims to predict protein misfolding and develop earlier diagnostics and treatments. Nautilus plans Voyager Platform shipment in mid-2027 and expects approximately 20 proteoform assays by mid-2028.
Nautilus Biotechnology (NAUT) will report third-quarter 2026 financial results before market open on October 27, 2026.
Management will host a webcast conference call at 5:30 a.m. Pacific / 8:30 a.m. Eastern to discuss results, business developments and outlook. Live audio will be available in the Investors section at www.nautilus.bio.
Nautilus Biotechnology (NAUT) reported a peer-reviewed Nature Methods publication showcasing large-scale, single-molecule analysis of tau proteoforms using its Voyager platform and Iterative Mapping technology.
The study resolved 130 tau proteoform groups out of up to 768 feasible groups, detecting species at 0.1% abundance with a median coefficient of variation below 5.5%. Distinct, non-random combinations of disease-associated modifications were linked to Alzheimer’s and related dementias, suggesting new biomarker and drug-target opportunities. Nautilus is applying this validated approach to α-synuclein in Parkinson’s disease and AKT1 in oncology, with AKT1 expected to enter the Iterative Mapping Early Access Program in late 2026 and a roadmap toward roughly 20 proteoform assays by mid-2028.
Nautilus Biotechnology (NASDAQ: NAUT) reported second quarter 2026 results, highlighting its first-ever revenue of $0.2 million, driven by grant funding from the Michael J. Fox Foundation for an alpha-synuclein proteoform assay and initial services revenue from its Iterative Mapping Early Access Program.
Operating expenses were $15.9 million, down 7% from the prior-year quarter, leading to a net loss of $14.5 million versus $15.0 million a year ago. The company is reallocating resources to accelerate its proteoform applications roadmap, including Tau and oncology proteoform assays and the Voyager™ platform, with pre-orders expected in early 2027 and instrument shipments and consumable kits anticipated beginning mid 2027. Cash, cash equivalents and investments totaled $129.2 million as of June 30, 2026.
Nautilus Biotechnology (NASDAQ:NAUT) will release its second quarter 2026 financial results before market open on Tuesday, July 28, 2026.
Management will host a webcast conference call at 5:30 a.m. PT / 8:30 a.m. ET to discuss results, business developments, and outlook, accessible via the company’s investor website.
Nautilus Biotechnology (NASDAQ: NAUT) reported Q1 2026 results and business progress for the quarter ended March 31, 2026. Key highlights include launching an Iterative Mapping Early Access Program with Baylor College of Medicine as the first customer, appointment of Amber Faust as VP of Global Sales, and platform development for a next-generation assay.
Financials: Operating expenses were $16.1M, down 14% year-over-year; net loss was $14.7M versus $16.6M a year earlier; cash and investments totaled $143.4M as of March 31, 2026.
Nautilus Biotechnology (NASDAQ: NAUT) will report first quarter 2026 financial results before market open on April 28, 2026. Management will host a webcast and conference call at 5:30 a.m. PT / 8:30 a.m. ET to discuss results, business developments, and outlook. Live audio will be available on the company Investors website.
Nautilus Biotechnology (NASDAQ: NAUT) will participate in the Investor Summit Group Virtual Conference. Management is scheduled to present on Wednesday, March 25, 2026 at 10:00 a.m. PT / 1:00 p.m. ET. Live and archived webcasts will be available in the Investors section of the company website.
Investors can access the webcast at www.nautilus.bio.
Nautilus Biotechnology (NASDAQ: NAUT) named Baylor College of Medicine its first customer for the Iterative Mapping Early Access Program on March 18, 2026. Baylor will use the Nautilus Voyager™ Platform in an NIH U01-funded study to develop a computational multi-omics toolkit for high-resolution cancer isoform analysis.
The collaboration pairs Baylor’s computational expertise with Nautilus’ single-molecule proteomics and validated tau proteoforms assay to improve detection and quantification of protein isoforms and enable direct transcriptional–proteomic comparisons.